Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Oct;157(4):1277-81.
doi: 10.1016/S0002-9440(10)64643-3.

CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury

Affiliations

CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury

Y Moromizato et al. Am J Pathol. 2000 Oct.

Abstract

Extensive limbal injury is a leading cause of irreversible blindness. The destruction of corneal limbal stem cells often results in corneal neovascularization and an optically inferior epithelium. Previous work has shown that the neovascularization after limbal injury is vascular endothelial growth factor (VEGF)-dependent, with much of the VEGF emanating from the inflammatory cells that invade the cornea. Using a relevant mouse model of limbal injury, we examined the role of CD18 and intercellular adhesion molecule-1 (ICAM-1) in limbal injury-induced neovascularization. The results show that CD18- and ICAM-1-deficient mice developed 35% (n = 5, P = 0.003) and 36% (n = 5, P = 0.002) less neovascularization than strain-specific normal controls, respectively. The corneal neutrophil counts were similarly reduced by 51% (n = 5, P < 0.003) and 46% (n = 5, P < 0.006), respectively. When VEGF mRNA levels were analyzed, they were reduced by 66% (n = 3, P = 0.004) and 48% (n = 3, P = 0.024), respectively. Taken together, these data identify CD-18 and ICAM-1 as mediators of the inflammatory and VEGF-dependent corneal neovascularization that follows limbal injury. The targeting of CD18 and ICAM-1 may prove useful in the treatment of inflammation-associated neovascularization in the cornea and elsewhere.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Examples of corneal neovascularization 7 days after epithelial debridement. The corneas come from a normal C57BL6J mouse (left), an ICAM-1-deficient mouse (middle), and a CD18-deficient mouse (right). Vessels were highlighted via intravenous injections of fluorescein-linked Lycopersicon esculentum lectin. KO, knockout. Original magnification, ×5.12; scale bar, 100 μm. Image size of 200 × 300 pixels is shown from the acquired image of 624 × 480 pixels.
Figure 2.
Figure 2.
Percent area of corneal neovascularization 2, 4, and 7 days after epithelial debridement. The area of neovascularization is shown as the percent of total corneal area. KO, knockout. *, Denotes P < 0.05 versus other conditions at same time point.
Figure 3.
Figure 3.
The total number of PMN in five standardized high-power fields from corneas 2, 4, and 7 days after epithelial debridement. KO, knockout. *, Denotes P < 0.05 versus other conditions at same time point.
Figure 4.
Figure 4.
VEGF mRNA levels normalized to 18S mRNA, expressed in arbitrary densitometry units, from corneas harvested 2, 4, and 7 days after epithelial debridement. KO, knockout. *, Denotes P < 0.05 versus other conditions at same time point.

References

    1. Tsai RJ, Sun TT, Tseng SC: Comparison of limbal and conjunctival autograft transplantation in corneal surface reconstruction in rabbits. Ophthalmology 1990, 97:446-455 - PubMed
    1. Huang AJW, Watson BD, Hernandez E, Tseng SCG: Induction of conjunctival transdifferentiation on vascularized corneas by photothrombotic occlusion of corneal neovascularization. Ophthalmology 1988, 95:228-235 - PubMed
    1. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP: Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998, 39:18-22 - PubMed
    1. Wilson RW, Ballantyne CM, Smith CW, Montgomery C, Bradley A, O’Brien WE, Beaudet AL: Gene targeting yields a CD18-mutant mouse for study of inflammation. J Immunol 1993, 151:1571-1578 - PubMed
    1. Sligh JE, Ballantyne CM, Rich SS, Hawkins HK, Smith CW, Bradley A, Beaudet AL: Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1993, 90:8529-8533 - PMC - PubMed

Publication types